Chickamauga, GA, United States of America

Michael A Ellis

USPTO Granted Patents = 19 

 

Average Co-Inventor Count = 1.8

ph-index = 5

Forward Citations = 94(Granted Patents)


Location History:

  • San Francisco, CA (US) (1997)
  • Sacramento, CA (US) (1998)
  • Landenberg, PA (US) (2014)
  • Glenelg, MD (US) (2014)
  • Dalton, GA (US) (2016 - 2017)
  • Boston, MA (US) (2017)
  • Chicago, IL (US) (2018)
  • Kirkland, WA (US) (2018)
  • Chattanooga, TN (US) (2020)
  • Clifton Park, NY (US) (2012 - 2021)
  • Chickamauga, GA (US) (2012 - 2022)
  • Lookout Mountain, GA (US) (2023)

Company Filing History:


Years Active: 1997-2023

Loading Chart...
Loading Chart...
19 patents (USPTO):

Title: Michael Ellis: Innovator in Bromodomain Inhibition

Introduction

Michael Ellis, a prolific inventor based in Clifton Park, NY, has made significant strides in the field of pharmaceuticals with a focus on bromodomain inhibitors. With a total of six patents to his name, Ellis is recognized for his innovative approaches to enhancing therapeutic options for various medical conditions.

Latest Patents

Among his latest contributions are two notable patents that focus on substituted bicyclic compounds as bromodomain inhibitors. These inventions detail the utility of these compounds for inhibiting BET protein function by binding to bromodomains. Furthermore, they encompass pharmaceutical compositions that include these compounds and outline their applications in therapy, showcasing the potential for advancements in medical treatment protocols.

Career Highlights

Throughout his career, Michael Ellis has collaborated with esteemed companies in the biotechnology sector, including Zenith Epigenetics Corporation and Sequoia Sciences, Inc. His work has significantly impacted the development of innovative therapeutic solutions, underlining his dedication and expertise in the field of pharmaceuticals and biochemistry.

Collaborations

In his journey as an inventor, Ellis has worked alongside talented individuals such as Shuang Liu and John Frederick Quinn. These collaborations highlight the importance of teamwork in driving research and innovation, showcasing how collective efforts can lead to significant breakthroughs in science and health.

Conclusion

Michael Ellis exemplifies the spirit of innovation within the pharmaceutical industry. With his focus on bromodomain inhibitors and a successful track record of patents, he continues to contribute to the advancement of medical therapies. His work not only reflects his brilliance as an inventor but also underscores the collaborative nature of scientific progress.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…